Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab + nUVB in Atopic Dermatitis
NCT05285839Phase 4Recruiting
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by Psoriasis Treatment Center of Central New Jersey. Started Apr 2022; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05285839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285839.